Key result
ESC 0/1 h pathway yields ~99% pooled rule-out sensitivity, outperforming 0/3 h and High-STEACS protocols.
Why the study?
Despite near-universal uptake of high-sensitivity cardiac troponins, there is considerable variability in how to assess acute chest pain patients.
Do accelerated diagnostic protocols (such as the ESC 0/1 h and High-STEACS pathways) using high-sensitivity cardiac troponins improve rule-out safety and Emergency Department efficiency compared to the ESC 0/3 h pathway or conventional sampling in patients with suspected myocardial infarction?
Do accelerated diagnostic protocols (such as the ESC 0/1 h and High-STEACS pathways) using high-sensitivity cardiac troponins improve rule-out safety and Emergency Department efficiency compared to the ESC 0/3 h pathway or conventional sampling in patients with suspected myocardial infarction?
Answers are grounded in this paper and cite their sources.
This narrative review highlights that while the ESC 0/1 h and High-STEACS accelerated diagnostic pathways offer superior rule-out sensitivity for myocardial infarction compared to the ESC 0/3 h pathway, prospective real-world implementation trials are still needed to confirm their impact on Emergency Department efficiency and clinical decision-making safety.
There have been considerable developments in the analytic precision of cardiac troponins in the last three decades. Whilst there has been near-universal uptake of this technology, there is considerable variability in how to assess acute chest pain patients using high-sensitivity cardiac troponins. This review describes the historical narrative for cardiac troponins and details the evidence base behind decision rules, such as single sample rule-out, single sample rule-in, and accelerated diagnostic protocols (ADPs). There is particular focus on the European Society of Cardiology (ESC) 0/1 and 0/3 h and the high-STEACS ADPs. The ESC 0/3 h ADP appears to have reduced rule-out safety compared to both the ESC 0/1 h and high-STEACS ADP. However, whilst high-STEACS performed well in its validation population, external validation in the US has been less impressive and warrants further investigation. The ESC 0/1 h pathway has demonstrated strong rule-out performance, helped by its observational zone. However, real world implementation studies comparing these ADPs are required to understand their impact on Emergency Department efficiency and the safety of clinician decision-making.
No takes yet. Share an insight, caveat, or question.
Hatherley et al. (2026) conducted a review in Suspected myocardial infarction / acute chest pain. High-sensitivity cardiac troponin accelerated diagnostic protocols (ESC 0/1 h, ESC 0/3 h, High-STEACS, single sample rule-out/rule-in) vs. Conventional troponin testing or comparison between different accelerated diagnostic protocols was evaluated on Rule-out and rule-in diagnostic performance (sensitivity, specificity, NPV, PPV) for myocardial infarction and 30-day MACE.
Synapse has enriched 10 related papers. Consider them for comparative context: